Abstract: A vascular occlusion catheter for at least partial occlusion of a target vessel includes proximal and distal shafts, with an occlusion balloon connected therebetween. The proximal shaft has a proximal internal lumen, in fluid communication with the occlusion balloon. The distal shaft has a distal internal lumen. A hypotube having an internal lumen extends through the proximal lumen and the occlusion balloon and into communication with the distal lumen. The catheter includes at least one of (i) a distal sensor positioned within the distal lumen and facing an opening formed in the distal shaft, or (ii) the proximal shaft further includes a sensor lumen, and a proximal sensor is positioned within the sensor lumen and facing an opening formed in the proximal shaft. A display hub is mounted to the proximal shaft, and is electrically connected with the at least one of the distal sensor or the proximal sensor.

Abstract: An occlusion catheter system is provided for at least partial occlusion of a vessel. The occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is fluidly connected to the proximal hub. An occlusion balloon has a proximal balloon end and a distal balloon end, the proximal balloon end being fluidly connected to the inflation catheter member. A distal catheter member is connected to the distal balloon end and includes an atraumatic tip on a distal end thereof, the atraumatic tip having a substantially circular profile in one configuration. The occlusion balloon, the inflation catheter member and the distal catheter member have a greatest outer diameter of less than 7 Fr in an uninflated condition.

Abstract: An inflation control system is provided for use with an occlusion catheter having an inflatable occlusion member for at least partial occlusion of a patient vessel. The inflation control system includes a fluid source in fluid communication with the inflatable occlusion member, a pressure source coupled to the fluid source and configured to move fluid between the fluid source and the inflatable occlusion member, and a controller operably coupled to the pressure source. The controller is configured to receive at least one patient vital sign as feedback and operate the pressure source to modulate an inflation volume of the occlusion member based, at least in part, on the feedback.

Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

Abstract: A mouth-opening measuring device includes a first end and an opposing second end. The width of the first end is less than the width of the second end such that the different widths on the first and second ends provide for different mouth opening abilities of an individual when either the first end or the second end is inserted into an individual's mouth.

Abstract: An occlusion catheter system is provided for at least partial occlusion of a vessel. The occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is fluidly connected to the proximal hub. An occlusion balloon has a proximal balloon end and a distal balloon end, the proximal balloon end being fluidly connected to the inflation catheter member. A distal catheter member is connected to the distal balloon end and includes an atraumatic tip on a distal end thereof, the atraumatic tip having a substantially circular profile in one configuration. The occlusion balloon, the inflation catheter member and the distal catheter member have a greatest outer diameter of less than 7 Fr in an uninflated condition.

Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

Abstract: The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

Abstract: The present invention pertains to the field of imparting or increasing resistance against fungal pathogens, in particular soy-beanrust, in plants, plant parts, and/or plant cells. This is achieved by increasing the content of scopoletin, scopolin and/or, most preferably, scoparone (6,7-di-methoxycoumarin) in a plant, plant part and/or plant cell. This can in particular be achieved by establishing and/or increasing the expression of an OMT3 enzyme and an F6H1 protein in the respective plant, plant part and/or plant cell; a further way would be to apply a formulation or solution containing scopoletin and/or, most preferably, scoparone to the plant, plant part and/or plant cell. The invention correspondingly also provides proteins, enzymes, expression constructs, plants, plant parts and/or plant cells. In this respect the invention also provides variants of the OMT3 enzyme.

Abstract: The present invention relates to genes and materials for improving plant health, preferably against phytopathogenic microorganisms, and/or against coumarin-induced adverse effects on plant health. Furthermore, the invention pertains to methods and uses of such genes and mate-rials for creating correspondingly beneficial plant cells, plant parts and whole plants, and also relates to products obtained from such plants or plant parts.

Abstract: The present invention is directed to a modified clostridial neurotoxin comprising a botulinum neurotoxin A (BoNT/A) Hcc domain, wherein the Hcc domain comprises a modification of methionine 1144 (MI 144), and wherein the modification increases oxidative resistance of the modified clostridial neurotoxin when compared to an otherwise identical clostridial neurotoxin lacking the modification. Also provided are (inter alia) corresponding methods for producing the same, methods for selecting oxidation resistant clostridial neurotoxins, nucleic acids encoding the same, and therapeutic uses of said modified clostridial neurotoxins.

Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesotheiin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesotheiin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesotheiin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesotheiin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: The technology relates in part to binding molecules that specifically bind to a polypeptide that is the Isoform 2 of mesothelin, or that specifically bind to an antigenic determinant (epitope) of the isoform 2 of mesothelin, or that specifically bind to polypeptides containing an antigenic determinant (epitope) of the isoform 2 of mesothelin, chimeric PD1 receptors that bind to PD ligands such as PDLs, to polynucleotides including vectors that encode such binding molecules, to ceils presenting such binding molecules and to methods of making such cells, to humanized forms of the binding molecules, and to methods of using such binding molecules, such as for treating cancers (e.g., ovarian cancers and mesotheliomas), including cancers in which the Isoform 2 of mesothelin is specifically expressed and/or upregulated relative to normal tissues.

Abstract: A machine for comminuting laminated glass members, such as automotive windshields and architectural glass, comprises infeed rollers feeding the member over a breaker bar, where an impactor assembly breaks the glass into small fragments and the plastic disposed between layers of the glass member into larger fragments, so that a size-based separation may be employed. The speed of the infeed rollers is controlled responsive to the thickness of the glass member.

Abstract: A vascular occlusion catheter for at least partial occlusion of a target vessel includes proximal and distal shafts, with an occlusion balloon connected therebetween. The proximal shaft has a proximal internal lumen, in fluid communication with the occlusion balloon. The distal shaft has a distal internal lumen. A hypotube having an internal lumen extends through the proximal lumen and the occlusion balloon and into communication with the distal lumen. The catheter includes at least one of (i) a distal sensor positioned within the distal lumen and facing an opening formed in the distal shaft, or (ii) the proximal shaft further includes a sensor lumen, and a proximal sensor is positioned within the sensor lumen and facing an opening formed in the proximal shaft. A display hub is mounted to the proximal shaft, and is electrically connected with the at least one of the distal sensor or the proximal sensor.

Abstract: An occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is connected to the proximal hub and has an inflation lumen. A stiffener member defines a longitudinal axis. The proximal end of the stiffener member is connected to the proximal hub. The stiffener member extends through a portion of the inflation lumen. An occlusion balloon has a proximal balloon end and a distal balloon end. A distal catheter member is positioned substantially on the longitudinal axis and is connected to the distal end of the stiffener member. An atraumatic tip is positioned on a distal end of the distal catheter member. The atraumatic tip has a substantially circular profile in a relaxed configuration. A pressure sensor is connected to the occlusion catheter system distally relative to the occlusion balloon and is connected to a processor by electrical wiring.

Abstract: An occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is connected to the proximal hub and has an inflation lumen. A stiffener member defines a longitudinal axis. The proximal end of the stiffener member is connected to the proximal hub. The stiffener member extends through a portion of the inflation lumen. An occlusion balloon has a proximal balloon end and a distal balloon end. A distal catheter member is positioned substantially on the longitudinal axis and is connected to the distal end of the stiffener member. An atraumatic tip is positioned on a distal end of the distal catheter member. The atraumatic tip has a substantially circular profile in a relaxed configuration. A pressure sensor is connected to the occlusion catheter system distally relative to the occlusion balloon and is connected to a processor by electrical wiring.

Abstract: A mouth-opening measuring device includes a first end and an opposing second end. The width of the first end is less than the width of the second end such that the different widths on the first and second ends provide for different mouth opening abilities of an individual when either the first end or the second end is inserted into an individual's mouth.

Abstract: The present invention pertains to the field of imparting or increasing resistance against fungal pathogens, in particular soy-beanrust, in plants, plant parts, and/or plant cells. This is achieved by increasing the content of scopoletin, scopolin and/or, most preferably, scoparone (6,7-di-methoxycoumarin) in a plant, plant part and/or plant cell. This can in particular be achieved by establishing and/or increasing the expression of an OMT3 enzyme and an F6H1 protein in the respective plant, plant part and/or plant cell; a further way would be to apply a formulation or solution containing scopoletin and/or, most preferably, scoparone to the plant, plant part and/or plant cell. The invention correspondingly also provides proteins, enzymes, expression constructs, plants, plant parts and/or plant cells. In this respect the invention also provides variants of the OMT3 enzyme.